245 related articles for article (PubMed ID: 27432915)
1. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
[TBL] [Abstract][Full Text] [Related]
2. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
[TBL] [Abstract][Full Text] [Related]
3. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
[TBL] [Abstract][Full Text] [Related]
4. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of age in 5631 patients with Wilms tumour prospectively registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001.
Hol JA; Lopez-Yurda MI; Van Tinteren H; Van Grotel M; Godzinski J; Vujanic G; Oldenburger F; De Camargo B; Ramírez-Villar GL; Bergeron C; Pritchard-Jones K; Graf N; Van den Heuvel-Eibrink MM
PLoS One; 2019; 14(8):e0221373. PubMed ID: 31425556
[TBL] [Abstract][Full Text] [Related]
6. Gain of 1q is a marker of poor prognosis in Wilms' tumors.
Segers H; van den Heuvel-Eibrink MM; Williams RD; van Tinteren H; Vujanic G; Pieters R; Pritchard-Jones K; Bown N;
Genes Chromosomes Cancer; 2013 Nov; 52(11):1065-74. PubMed ID: 24038759
[TBL] [Abstract][Full Text] [Related]
7. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
van den Heuvel-Eibrink MM; van Tinteren H; Bergeron C; Coulomb-L'Hermine A; de Camargo B; Leuschner I; Sandstedt B; Acha T; Godzinski J; Oldenburger F; Gooskens SL; de Kraker J; Vujanic GM; Pritchard-Jones K; Graf N
Eur J Cancer; 2015 Mar; 51(4):498-506. PubMed ID: 25592561
[TBL] [Abstract][Full Text] [Related]
8. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
9. [Nephroblastoma - 30-years period of its treatment in the University Hospital Motol, Prague].
Mališ J; Švojgr K; Pýcha K; Jeřábková V; Cyprová S; Churáčková M; Šmelhaus V; Radvanský J; Zítková M; Kodet R; Kodetová D; Malinová B; Koutecký J; Šnajdauf J; Starý J
Klin Onkol; 2013; 26(5):336-42. PubMed ID: 24107156
[TBL] [Abstract][Full Text] [Related]
10. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of histopathological response to preoperative chemotherapy in unilateral Wilms' tumor: An analysis of 899 patients treated on the SIOP WT 2001 protocol in the UK-CCLG and GPOH studies.
Vujanić GM; D'Hooghe E; Graf N; Vokuhl C; Al-Saadi R; Chowdhury T; Pritchard-Jones K; Furtwängler R
Int J Cancer; 2021 Sep; 149(6):1332-1340. PubMed ID: 34109628
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
Fernandez CV; Perlman EJ; Mullen EA; Chi YY; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G; Kalapurakal JA; Bocking T; Huff V; Tian J; Geller JI; Grundy PE; Anderson JR; Dome JS; Shamberger RC
Ann Surg; 2017 Apr; 265(4):835-840. PubMed ID: 27811504
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
[TBL] [Abstract][Full Text] [Related]
14. Clear cell sarcomas of the kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: a report of the SIOP Renal Tumour Study Group.
Furtwängler R; Gooskens SL; van Tinteren H; de Kraker J; Schleiermacher G; Bergeron C; de Camargo B; Acha T; Godzinski J; Sandstedt B; Leuschner I; Vujanic GM; Pieters R; Graf N; van den Heuvel-Eibrink MM
Eur J Cancer; 2013 Nov; 49(16):3497-506. PubMed ID: 23880476
[TBL] [Abstract][Full Text] [Related]
15. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002-2020).
Vujanić GM; Mifsud W; Chowdhury T; Al-Saadi R; Pritchard-Jones K;
Cancer; 2022 Apr; 128(8):1666-1675. PubMed ID: 35119702
[TBL] [Abstract][Full Text] [Related]
17. Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocols.
Groenendijk A; van Tinteren H; Jiang Y; de Krijger RR; Vujanic GM; Godzinski J; Rübe C; Schenk JP; Morosi C; Pritchard-Jones K; Al-Saadi R; Vaidya SJ; Verschuur AC; Ramírez-Villar GL; Graf N; de Camargo B; Drost J; Perotti D; van den Heuvel-Eibrink MM; Brok J; Spreafico F; Mavinkurve-Groothuis AMC
Eur J Cancer; 2022 Mar; 163():88-97. PubMed ID: 35042071
[TBL] [Abstract][Full Text] [Related]
18. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP).
Kilday JP; Mitra B; Domerg C; Ward J; Andreiuolo F; Osteso-Ibanez T; Mauguen A; Varlet P; Le Deley MC; Lowe J; Ellison DW; Gilbertson RJ; Coyle B; Grill J; Grundy RG
Clin Cancer Res; 2012 Apr; 18(7):2001-11. PubMed ID: 22338015
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification for wilms tumor: current approach and future directions.
Dome JS; Perlman EJ; Graf N
Am Soc Clin Oncol Educ Book; 2014; ():215-23. PubMed ID: 24857079
[TBL] [Abstract][Full Text] [Related]
20. Optimal neoadjuvant chemotherapy duration in Wilms tumour with intravascular thrombus: A literature review and evidence from SIOP WT 2001 trial.
Morris L; Squire R; Sznajder B; van Tinteren H; Godzinski J; Powis M
Pediatr Blood Cancer; 2019 Nov; 66(11):e27930. PubMed ID: 31339231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
